Dominic M. Homac sued Sanofi-Aventis and Regeneron on Oct. 23, 2026, alleging Dupixent caused or accelerated his cutaneous T-cell lymphoma.
Cutaneous T-cell lymphoma, or CTCL, is a rare cancer of infection-fighting T-cells that first shows up in the skin. Homac filed in the U.S. District Court for the Middle District of Florida after Dupixent treatment for eczema, according to AboutLawsuits reporting on the Homac filing AboutLawsuits account of the complaint. His case is one of the CTCL injury claims now moving through federal court.
Official resources:
- Read the official notice from Uscourts — Use this primary source to verify the official announcement.
- Read the original report from FDA — Use this primary source to review the complete report.
Table of Contents
- What the new lawsuit alleges
- Where federal Dupixent cases stand
- What regulators and the label say
- What patients and families can do now
What the new lawsuit alleges
Homac alleges Dupixent caused or worsened his CTCL rather than treating simple eczema. The complaint names Sanofi-Aventis and Regeneron, the companies behind Dupixent.
The broader lawsuits focus on patients treated for eczema or atopic dermatitis. They allege Dupixent can mask CTCL, delay its diagnosis, or accelerate the disease. Named CTCL forms include mycosis fungoides and Sezary syndrome, two subtypes that start with rash-like skin patches and plaques.
Where federal Dupixent cases stand
Federal CTCL cases were centralized on June 4, 2026 as MDL No. 3180, In re: Dupixent Products Liability Litigation. The Judicial Panel on Multidistrict Litigation assigned the cases to the District of New Jersey before Judge Zahid N. Quraishi, as shown in the panel's transfer order. At least 40 federal cases were pending in the MDL on the Nov.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
2, 2026 panel report. The court now permits new CTCL claims to be filed directly in New Jersey. Plaintiffs' co-lead counsel have been appointed, including Christopher Seeger, as case-management proceedings move forward. Centralization does not decide fault. It coordinates discovery, rulings, and trial preparation.
What regulators and the label say
The FDA listed "Dupixent injection — cutaneous T-cell lymphoma" in its October–December 2024 potential-signal report. The agency said it was evaluating whether regulatory action was needed, as described in the FDA signal report. The current U.S. prescribing information warns about hypersensitivity, eye inflammation, and other reactions.
It contains no lymphoma or CTCL warning, based on labeling updated in June 2025. Causation remains unproven. CTCL can closely mimic eczema, so some cases may reflect an initial misdiagnosis that became clearer during Dupixent treatment. That "unmasking" question is central to both medicine and the lawsuits.
What patients and families can do now
People treated with Dupixent for eczema who later received a CTCL diagnosis are the group these cases concern. Key records include prescription dates, dermatology visits, biopsy reports, and pathology slides.
A products-liability lawyer can compare that timeline against MDL filing rules and deadlines. Bring the medication list and biopsy file to that review.
- List every eczema drug and start date, especially Dupixent
- Save biopsy, pathology, and staging reports
- Keep photos and notes showing when rashes changed or spread
- Do not stop prescribed treatment without talking to the treating doctor
You Might Also Like
- Hair Relaxer Lawsuit Settlement Payouts Explained for November Claimants
- Breast Mesh Lawsuit Claims Linked to Internal Bra Complications
- Gabapentin Lawsuit Filings Rise Over Dementia Injury Claims